Pfizer said in a Dec. 12 news release that it is donating the rights to address concerns from antitrust regulators related to its $43 billion deal to buy Seagen. The drugmaker received the required regulatory approvals and expects to close the deal on Dec. 14 after announcing the deal in March.
After the deal closes, Pfizer said it will create a separate cancer drugs operation led by Chris Boshoff, MD, PhD, who will serve as chief oncology officer and executive vice president. The new structure and rights agreement will go into effect January 1.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
